NAS:AXNX (USA)
Business Description
Axonics Inc
NAICS : 334510
SIC : 3841
26 Technology Drive, Irvine, CA, USA, 92618
Description
Axonics Inc is a United stated based medical technology company. It focuses on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention. The company has designed and developed the r-SNM System, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder and fecal incontinence.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 21.87 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 27.38 | |||||
| Beneish M-Score | -2.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 246.1 | |||||
| 3-Year EBITDA Growth Rate | 30.4 | |||||
| 3-Year EPS without NRI Growth Rate | 26.3 | |||||
| 3-Year FCF Growth Rate | 37.2 | |||||
| 3-Year Book Growth Rate | 26.4 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.95 | |||||
| 9-Day RSI | 62.56 | |||||
| 14-Day RSI | 63.05 | |||||
| 6-1 Month Momentum % | 16.42 | |||||
| 12-1 Month Momentum % | -5.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.49 | |||||
| Quick Ratio | 8.53 | |||||
| Cash Ratio | 7.14 | |||||
| Days Inventory | 352.94 | |||||
| Days Sales Outstanding | 48.63 | |||||
| Days Payable | 52.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.6 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.99 | |||||
| Operating Margin % | -30.78 | |||||
| Net Margin % | -35.19 | |||||
| ROE % | -16.09 | |||||
| ROA % | -14.1 | |||||
| ROIC % | -20.95 | |||||
| ROC (Joel Greenblatt) % | -97.78 | |||||
| ROCE % | -15.27 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 14.88 | |||||
| PB Ratio | 7.71 | |||||
| Price-to-Tangible-Book | 13.47 | |||||
| EV-to-EBIT | -41.9 | |||||
| EV-to-EBITDA | -48.89 | |||||
| EV-to-Revenue | 15.19 | |||||
| EV-to-FCF | -148.26 | |||||
| Price-to-Net-Current-Asset-Value | 14.31 | |||||
| Price-to-Net-Cash | 24.77 | |||||
| Earnings Yield (Greenblatt) % | -2.35 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:AXNX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 217.448 | ||
| EPS (TTM) ($) | -1.69 | ||
| Beta | 1 | ||
| Volatility % | 52.58 | ||
| 14-Day RSI | 63.05 | ||
| 14-Day ATR ($) | 3.092368 | ||
| 20-Day SMA ($) | 67.9485 | ||
| 12-1 Month Momentum % | -5.38 | ||
| 52-Week Range ($) | 38.41 - 79.81 | ||
| Shares Outstanding (Mil) | 48.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Axonics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||